New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 28, 2014
13:03 EDTHZNPHorizon Pharma shares offer 'significant value,' says Stifel
Stifel sees "significant value" in shares of Horizon Pharma with today's pullback and it keeps a Buy rating on the name. The firm says Express Scripts and Caremark putting Duexis and Vimovo on their exclusion lists is a "large disappointment," but it believes management has several avenues to offset the impact. Stifel lowered its price target for shares to $20 from $25.
News For HZNP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 30, 2015
16:22 EDTHZNPOn The Fly: Closing Wrap
Subscribe for More Information
13:48 EDTHZNPHyperion Therapeutics downgraded to Neutral from Buy at Roth Capital
Subscribe for More Information
12:22 EDTHZNPOn The Fly: Midday Wrap
Subscribe for More Information
11:49 EDTHZNPStreet Check: Hyperion bought after Brean noted takeout potential last month
Subscribe for More Information
11:02 EDTHZNPHyperion Therapeutics downgraded to Hold from Buy at Brean Capital
Brean Capital downgraded Hyperion Therapeutics (HPTX) citing the takeover by Horizon Pharma (HZNP). Brean views the buyout price as "reasonable and fair."
10:12 EDTHZNPHigh option volume stocks
Subscribe for More Information
07:02 EDTHZNPHorizon Pharma to host conference call
Conference call to discuss the acquisition of Hyperion Therapeutics (HPTX) will be held on March 30 at 8 am. Webcast Link
06:04 EDTHZNPHorizon Pharma to acquire Hyperion Therapeutics for $46.00 per share
Subscribe for More Information
06:01 EDTHZNPHorizon Pharma to acquire Hyperion Therapeutics for $46.00 per share
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use